Christopher Lindop
2009 - Haemonetics
In 2009, Christopher Lindop earned a total compensation of $2.1M as Chief Financial Officer Vice President of Business Development at Haemonetics, a 128% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $255,769 |
---|---|
Option Awards | $1,196,363 |
Salary | $400,548 |
Stock Awards | $236,949 |
Total | $2,089,628 |
Lindop received $1.2M in option awards, accounting for 57% of the total pay in 2009.
Lindop also received $255.8K in non-equity incentive plan, $400.5K in salary and $236.9K in stock awards.
Rankings
In 2009, Christopher Lindop's compensation ranked 2,276th out of 9,885 executives tracked by ExecPay. In other words, Lindop earned more than 77.0% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,276 out of 9,885 | 77th |
Division Manufacturing | 800 out of 3,690 | 78th |
Major group Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks | 123 out of 607 | 80th |
Industry group Surgical, Medical, And Dental Instruments And Supplies | 63 out of 331 | 81st |
Industry Surgical and Medical Instruments and Apparatus | 38 out of 217 | 83rd |
Source: SEC filing on June 17, 2010.
Lindop's colleagues
We found four more compensation records of executives who worked with Christopher Lindop at Haemonetics in 2009.